{"id":"placebo-hypogonadal","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1200667","moleculeType":"Small molecule","molecularWeight":"598.09"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"A placebo has no active pharmacological mechanism; it serves as a control arm in clinical studies of hypogonadism therapies. By comparing active treatment outcomes to placebo responses, researchers can isolate the true therapeutic effect of investigational hypogonadal interventions and account for natural disease progression and psychological effects.","oneSentence":"This is a placebo control used in clinical trials to assess the efficacy of hypogonadal treatments through comparison against an inert substance.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:04.254Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypogonadism (control arm in clinical trials)"}]},"trialDetails":[{"nctId":"NCT07235917","phase":"PHASE2","title":"A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-11","conditions":"Functional Hypothalamic Amenorrhea (FHA)","enrollment":34},{"nctId":"NCT04049331","phase":"PHASE2","title":"Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone","status":"RECRUITING","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2021-03-22","conditions":"Hypogonadism, Male, Fatigue Syndrome, Chronic","enrollment":240},{"nctId":"NCT03518034","phase":"PHASE4","title":"A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-05-03","conditions":"Hypogonadism, Cardiovascular Diseases","enrollment":5246},{"nctId":"NCT01460654","phase":"PHASE2","title":"Testosterone and Alendronate in Hypogonadal Men","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2011-10","conditions":"Hypogonadism, Osteopenia, Osteoporosis","enrollment":44},{"nctId":"NCT05484167","phase":"PHASE4","title":"Natesto Testosterone Nasal Gel for Hypogonadal Men","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2023-01-01","conditions":"Erectile Dysfunction, Sexual Dysfunction","enrollment":""},{"nctId":"NCT00136695","phase":"PHASE2","title":"Anastrozole Administration in Elderly Hypogonadal Men","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2004-10","conditions":"Hypogonadism","enrollment":88},{"nctId":"NCT00163566","phase":"PHASE2","title":"Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80","status":"COMPLETED","sponsor":"ASCEND Therapeutics","startDate":"2004-10","conditions":"Hypogonadism, Late Onset Hypogonadism, Low Testosterone","enrollment":128},{"nctId":"NCT00504712","phase":"PHASE4","title":"Testosterone for Peripheral Vascular Disease","status":"COMPLETED","sponsor":"Barnsley Hospital","startDate":"2006-02","conditions":"Hypogonadism, Peripheral Vascular Disease, Type 2 Diabetes","enrollment":24},{"nctId":"NCT01200862","phase":"PHASE2","title":"Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men","status":"TERMINATED","sponsor":"Mereo BioPharma","startDate":"2010-08","conditions":"Obese Hypogonadotropic Hypogonadism","enrollment":29},{"nctId":"NCT02433730","phase":"PHASE4","title":"Testosterone Therapy in Hypogonadal Men Treated With Opioids","status":"COMPLETED","sponsor":"Marianne Andersen","startDate":"2015-05-01","conditions":"Hypogonadism","enrollment":40},{"nctId":"NCT02419105","phase":"PHASE3","title":"Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2015-09","conditions":"Hypogonadism, Pre-frail Seniors","enrollment":91},{"nctId":"NCT03933618","phase":"PHASE2","title":"Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function","status":"COMPLETED","sponsor":"Albany Medical College","startDate":"2015-04-02","conditions":"Hypogonadism, Male","enrollment":24},{"nctId":"NCT00179517","phase":"PHASE2","title":"Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2001-06","conditions":"Seizure Disorder, Hypogonadism, Erectile Dysfunction","enrollment":40},{"nctId":"NCT03724955","phase":"PHASE4","title":"Pilot E2 for Hypogonadal Women With CFBD","status":"WITHDRAWN","sponsor":"Emory University","startDate":"2019-04","conditions":"Cystic Fibrosis Related Bone Disease","enrollment":""},{"nctId":"NCT03792321","phase":"PHASE4","title":"Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients\" (SETH2)","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-01-10","conditions":"Hypogonadism, Male, Diabetes Mellitus, Type 2, Obesity","enrollment":55},{"nctId":"NCT01748370","phase":"PHASE4","title":"Vitamin D Treatment and Hypogonadism in Men","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2012-12-01","conditions":"Hypogonadism","enrollment":200},{"nctId":"NCT02366975","phase":"PHASE4","title":"TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST","status":"COMPLETED","sponsor":"University of Florence","startDate":"2012-11","conditions":"Prostatic Hyperplasia, Lower Urinary Tract Symptoms, Hypogonadism","enrollment":143},{"nctId":"NCT01377103","phase":"NA","title":"Testosterone Therapy in Heart Failure","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2011-07","conditions":"Heart Failure, Hypogonadism","enrollment":""},{"nctId":"NCT00413244","phase":"PHASE3","title":"The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2007-01","conditions":"Coronary Artery Disease","enrollment":51},{"nctId":"NCT01816295","phase":"PHASE3","title":"A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-05","conditions":"Hypogonadism","enrollment":715},{"nctId":"NCT02443090","phase":"PHASE2","title":"Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men","status":"UNKNOWN","sponsor":"NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)","startDate":"2015-05","conditions":"Secondary Hypogonadism, Sexual Dysfunction, Erectile Dysfunction","enrollment":160},{"nctId":"NCT00433199","phase":"PHASE3","title":"Testosterone Treatment for Hypogonadal Men","status":"COMPLETED","sponsor":"Abbott","startDate":"2007-02","conditions":"Hypogonadism","enrollment":274},{"nctId":"NCT00141492","phase":"PHASE2","title":"Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes","status":"COMPLETED","sponsor":"Solvay Pharmaceuticals","startDate":"2004-10","conditions":"Type 2 Diabetes, Hypogonadism","enrollment":""},{"nctId":"NCT00328926","phase":"PHASE4","title":"Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2006-03","conditions":"Hypogonadotropic Hypogonadism","enrollment":11},{"nctId":"NCT00487734","phase":"PHASE4","title":"Effect of Testosterone Replacement on Insulin Resistance","status":"COMPLETED","sponsor":"McGuire Research Institute","startDate":"2007-08","conditions":"Metabolic Syndrome, Hypogonadism","enrollment":19},{"nctId":"NCT01346319","phase":"PHASE1","title":"Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.","status":"COMPLETED","sponsor":"Abbott","startDate":"2011-04","conditions":"Hypogonadal Males","enrollment":""},{"nctId":"NCT00355537","phase":"PHASE4","title":"Testosterone Replacement in Diabetes With Vascular Disease (Version 2)","status":"COMPLETED","sponsor":"Barnsley Hospital","startDate":"2006-02","conditions":"Diabetes Mellitus, Peripheral Vascular Disease","enrollment":19},{"nctId":"NCT00349362","phase":"PHASE4","title":"Testosterone for Men With Insulin Treated Type 2 Diabetes","status":"COMPLETED","sponsor":"Barnsley Hospital","startDate":"2006-07","conditions":"Hypogonadism, Diabetes","enrollment":40},{"nctId":"NCT00415571","phase":"PHASE2","title":"Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors","status":"COMPLETED","sponsor":"QuatRx Pharmaceuticals Company","startDate":"2006-12","conditions":"Hypogonadism, Erectile Dysfunction","enrollment":72},{"nctId":"NCT01061970","phase":"PHASE2","title":"Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Chronic Obstructive Pulmonary Disease That Are on Oral Glucocorticoid Therapy","status":"COMPLETED","sponsor":"QuatRx Pharmaceuticals Company","startDate":"2007-01","conditions":"Hypogonadism, Chronic Obstructive Pulmonary Disease","enrollment":15},{"nctId":"NCT00700024","phase":"PHASE4","title":"Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men","status":"UNKNOWN","sponsor":"Odense University Hospital","startDate":"2008-04","conditions":"Hypogonadism, Metabolic Syndrome","enrollment":60},{"nctId":"NCT00696748","phase":"PHASE3","title":"The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men","status":"UNKNOWN","sponsor":"Russian Academy of Medical Sciences","startDate":"2005-10","conditions":"Metabolic Syndrome, Hypogonadism","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo hypogonadal","genericName":"Placebo hypogonadal","companyName":"Medical University of Graz","companyId":"medical-university-of-graz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo control used in clinical trials to assess the efficacy of hypogonadal treatments through comparison against an inert substance. Used for Hypogonadism (control arm in clinical trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}